Open AccessInterleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials
Author(s) -
Antonio Abbate,
George Wohlford,
Marco Giuseppe Del Buono,
Juan Guido Chiabrando,
Roshanak Markley,
Jeremy Turlington,
Dinesh Kadariya,
Cory Trankle,
Giuseppe BiondiZoccai,
Michael J. Lipinski,
Benjamin Van Tassell
Publication year - 2021
Publication title -
european heart journal. cardiovascular pharmacotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.895
H-Index - 26
eISSN - 2055-6845
pISSN - 2055-6837
DOI - 10.1093/ehjcvp/pvab075
Subject(s) - anakinra , medicine , myocardial infarction , heart failure , placebo , incidence (geometry) , cardiology , randomized controlled trial , clinical endpoint , gastroenterology , pathology , disease , physics , alternative medicine , optics
ST-segment elevation myocardial infarction (STEMI) is associated with an intense acute inflammatory response and an increased risk of death and heart failure (HF). In this study, we sought to evaluate the effect of anakinra, a recombinant interleukin-1 receptor antagonist, on the incidence of HF.